Araclon Biotech Presents Positive Final Results from Phase
Trial met primary endpoints, confirming vaccine’s safety, tolerability and robust immune response against the Aβ40 peptide in early-stage Alzheimer's...
Source: globenewswire.com
Stay updated with breaking news from Teaes Tesaes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Trial met primary endpoints, confirming vaccine’s safety, tolerability and robust immune response against the Aβ40 peptide in early-stage Alzheimer's...